Related Experiment Video
Updated: Jun 1, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Measuring mortality reductions in cancer screening trials.
1Department of Epidemiology, Biostatistics and Occupational Health, Purvis Hall, 1020 Pine Avenue West, McGill University, Montreal, Que´bec, H3A 1A2, Canada. james.hanley@mcgill.ca
Epidemiologic Reviews
|June 1, 2011
Summary
Cancer screening trials often underestimate mortality reductions due to flawed calculations. Proper analysis reveals greater benefits with continued screening for prostate, breast, and colorectal cancers.
Area of Science:
- Oncology
- Biostatistics
- Public Health
Background:
- Randomized trials assess cancer screening effectiveness.
- Reported mortality reductions are often modest.
- Inappropriate calculation methods may distort trial results.
Purpose of the Study:
- To re-evaluate mortality reductions in cancer screening trials.
- To address the timing and extent of reductions using time-specific mortality ratios.
- To highlight the impact of analytical methods on reported screening benefits.
Main Methods:
- Review of randomized trials for prostate, breast, and colorectal cancer screening.
- Application of time-specific mortality ratios for analysis.
- Consideration of disease natural history, screening frequency, and follow-up duration.
Main Results:
- Reported mortality reductions in literature are substantially underestimated.
- A time-dependent pattern of mortality reduction exists, influenced by screening continuity.
- Inappropriate analyses distort the true impact of screening interventions.
Conclusions:
- Continued cancer screening yields greater mortality reductions than commonly reported.
- Accurate analysis of screening trial data is crucial for understanding true benefits.
- Optimized screening strategies require consideration of disease dynamics and analytical methods.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:20Actuarial Approach
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
01:09Truncation in Survival Analysis
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.